Achieve Life Sciences, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on August 14, 2026, establishing an at-the-market equity offering program allowing the sale of up to $150.0 million in common stock. Jefferies will act as sales agent and receive compensation of up to 3.0% of gross proceeds. The company intends to use net proceeds for the commercialization of cytisinicline, funding a Phase 3 clinical trial for e-cigarette cessation, and general corporate purposes. Achieve Life Sciences operates in the biotechnology industry, focusing on developing treatments for addiction.
